Research Topics
| G J S RustinSummaryAffiliation: Mount Vernon Cancer Centre Country: UK Publications
| Collaborators
|
Detail Information
Publications
Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumorsG J Rustin
Department of Medical Oncology, Charing Cross Hospital, London, United Kingdom
J Clin Oncol 14:2769-73. 1996..More patient years at risk enabled a further analysis of the risk of second tumors to be performed in the 1,377 women treated in this until up to 1990...- Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancerGordon J S Rustin
Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom
Clin Cancer Res 10:3919-26. 2004 - Use of CA-125 to assess response to new agents in ovarian cancer trialsGordon J S Rustin
Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom
J Clin Oncol 21:187s-193s. 2003..These definitions already have been shown to be valuable in assessing efficacy of new agents but require further prospective evaluation... - Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic resultsGordon J S Rustin
Department of Medical Oncology, Mount Vernon Hospital, Northwood, Middlesex HA6 2RN, United Kingdom
J Clin Oncol 21:2815-22. 2003..A phase I trial was performed with combretastatin A4 phosphate (CA4P), a novel tubulin-binding agent that has been shown to rapidly reduce blood flow in animal tumors... - 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic studyG J S Rustin
Department of Medical Oncology, Mount Vernon Hospital, Northwood, Middlesex, UK
Br J Cancer 88:1160-7. 2003..There was one unconfirmed partial response at 1300 mg x m(-2). In conclusion, DMXAA is a novel vascular targeting agent and is well tolerated... - Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levelsG J Rustin
Department of Medical Oncology, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
J Clin Oncol 19:4054-7. 2001..To determine an accurate definition for progression of ovarian cancer in patients with a persistently elevated serum CA-125... - Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trialsG J Rustin
Cancer Treatment Centre, and Gray Laboratory, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
J Clin Oncol 18:1733-9. 2000..To determine whether precise definitions of response based on serial CA-125 levels can predict the activity of drugs in phase II trials for ovarian cancer as accurately as standard criteria... - Use of tumour markers in monitoring the course of ovarian cancerG J Rustin
Mount Vernon Hospital, Northwood, UK
Ann Oncol 10:21-7. 1999..There is a need to delineate how the best available serum marker for ovarian cancer, CA 125 should be used in monitoring the treatment of individual patients, and in clinical trials... - Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumoursI A McNeish
Department of Medical Oncology, Imperial College School of Medicine, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK
Br J Cancer 90:1169-75. 2004..Our results suggest that Carbop-EC-T may enable a greater proportion of patients with relapsed and refractory GCTs to enter long-term remission... - Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours - a retrospective long-term follow-up studyJ Gaffan
Department of Medical Oncology, Charing Cross Campus of Imperial College London, Fulham Palace Rd, London W6 8RF, UK
Br J Cancer 89:1849-54. 2003..In conclusion, the risk of chemotherapy-induced infertility is low in both male and female GCT patients and does not clearly correlate with the cumulative cisplatin dose... - A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancerA E Guppy
Department of Medical Oncology, The Clocktower, Mount Vernon Centre for Cancer Treatment, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK
Br J Cancer 90:810-4. 2004..61 months, respectively. This study demonstrates that sequential chemotherapy with just two initial courses of carboplatin is a reasonable way to introduce new agents into first-line therapy for poor prognostic ovarian cancer patients... - Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000I A McNeish
Department of Medical Oncology, Trophoblastic Tumour Screening and Treatment Center, Charing Cross Hospital, London, United Kingdom
J Clin Oncol 20:1838-44. 2002..Simplifying the stratification of GTD into two classes (low- and high-risk) does not compromise overall outcome and may reduce the risk of second tumors... - A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sitesD M Patterson
Department of Medical Oncology, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
Int J Gynecol Cancer 18:43-50. 2008..We question the need for potentially toxic adjuvant chemotherapy in nondysgerminoma patients who have greater than 90% chance of being salvaged with chemotherapy if they relapse later... - Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trialGordon J S Rustin
Mount Vernon Cancer Centre, Northwood, UK
Lancet 376:1155-63. 2010..In the MRC OV05/EORTC 55955 collaborative trial, we aimed to establish the benefits of early treatment on the basis of increased CA125 concentrations compared with delayed treatment on the basis of clinical recurrence... - CA125 response: can it replace the traditional response criteria in ovarian cancer?A E Guppy
Department of Medical Oncology, Mount Vernon Centre for Cancer Treatment, Northwood, Middlesex, United Kingdom
Oncologist 7:437-43. 2002..These precise definitions are currently being prospectively validated in conjunction with the new response evaluation criteria in solid tumor response guidelines and are being incorporated into all future clinical trials... - Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancerM Zweifel
Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK
Ann Oncol 22:2036-41. 2011..A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian cancer... - Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performedG J S Rustin
Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, UK
Ann Oncol 22:viii45-viii48. 2011..Only one randomized trial has examined the value of performing routine CA125 measurements during follow-up of ovarian cancer. The results of this trial and implications of frequent CA125 measurements are examined... - Vascular damaging agentsD M Patterson
Department of Medical Oncology, Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK
Clin Oncol (R Coll Radiol) 19:443-56. 2007..The optimal use and scheduling of AIs and VDAs remains to be determined. Further understanding of the mechanisms of action of these potentially very exciting anti-neoplastic agents is urgently required... - A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanomaS J Strauss
Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK
Br J Cancer 89:1901-5. 2003..Preliminary information on efficacy demonstrates that it is unlikely that the combination can be given in doses sufficient to improve on the efficacy of temozolomide alone... - Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRIK J Lankester
Department of Medical Oncology, Mount Vernon Hospital, Rickmansworth Rd, Northwood, Middlesex HA6 2RN, UK
Br J Cancer 93:979-85. 2005..Therefore, if combination therapy does show changes in DCE-MRI parameters then the effects can be attributed to antivascular therapy rather than chemotherapy... - Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal populationH E Lambert
Department of Clinical Oncology, Hammersmith Hospital, London, UK
Int J Gynecol Cancer 14:772-8. 2004..Women with advanced ovarian cancer have an improved chance of long-term survival following treatment if they present with minimal residual disease after primary surgical debulking, grade 1 tumors, and good performance status... - Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trialR T D Oliver
Department of Medical Oncology, St Bart s and the London Hospital, London EC1A 7BE, UK
Lancet 366:293-300. 2005..After good results in initial studies with one injection of carboplatin, we undertook a large randomised trial to compare the approaches of radiotherapy with chemotherapy in seminoma treatment... - Epithelial ovarian cancer: a review of current managementA E Guppy
Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, UK
Clin Oncol (R Coll Radiol) 17:399-411. 2005..In this paper we review the literature on the epidemiology, pathology, clinical features and the current treatment options in epithelial ovarian cancer... - Vascular disrupting agents: a new class of drug in cancer therapyA M Gaya
Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, UK
Clin Oncol (R Coll Radiol) 17:277-90. 2005..To provide a comprehensive overview of the current state of development of a novel class of anti-cancer drugs, the vascular disrupting agents (VDAs), previously known as vascular targeting agents (VTAs)... - Lactate dehydrogenase is not a useful marker for relapse in patients on surveillance for stage I germ cell tumoursC Ackers
Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK
Br J Cancer 94:1231-2. 2006..Routine measurement of LDH in patients on surveillance for stage I germ cell tumours does not add to the early detection of relapse... - Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrationsTyronne I Goonewardene
Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, UK
Lancet Oncol 8:813-21. 2007..Asymptomatic patients with rising CA-125 concentrations provide an ideal group in which to test new investigational agents that might have potential as maintenance treatment... - Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysisSusan M Galbraith
Gray Cancer Institute, Mount Vernon Hospital, Middlesex HA6 2JR, UK
NMR Biomed 15:132-42. 2002..Pixel analyses slightly improve reproducibility estimates and retain information about spatial heterogeneity. Reproducibility studies are recommended when treatment effects are being monitored... - Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imagingSusan M Galbraith
Department of Medical Oncology and Paul Strickland Scanner Centre, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
J Clin Oncol 20:3826-40. 2002..CONCLUSION: DMXAA significantly reduces DCE-MRI parameters related to tumor blood flow, over a wide dose range, consistent with the reported tumor vascular targeting activity. Further clinical evaluation of DMXAA is warranted... - Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)Gordon J S Rustin
J Natl Cancer Inst 96:487-8. 2004 - Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologueGary J Kelloff
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892, USA
Clin Cancer Res 10:3881-4. 2004 - Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imagingSusan M Galbraith
Department of Medical Oncology, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
J Clin Oncol 21:2831-42. 2003.... - Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamideGordon J S Rustin
Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom
J Clin Oncol 24:45-51. 2006..Retrospectively, we determined whether the use of this CA-125 definition in a randomized trial would have shown the same magnitude of difference between the treatment arms as was shown when the standard progression definition was used... - Management of brain metastases in patients with high-risk gestational trophoblastic tumorsEdward S Newlands
Department of Medical Oncology, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, U K
J Reprod Med 47:465-71. 2002..To analyze the results of current treatment of patients with brain metastases from high-risk gestational trophoblastic tumors... - Progress in the management of gynecologic cancer: consensus summary statementStephen A Cannistra
Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital, Boston, USA
J Clin Oncol 21:129s-132s. 2003 - 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study GroupRobert A Huddart
Academic Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, UK
J Clin Oncol 25:3090-5. 2007.... - Can we now agree to use the same definition to measure response according to CA-125?Gordon J S Rustin
J Clin Oncol 22:4035-6. 2004 - Dynamic MRI for imaging tumor microvasculature: comparison of susceptibility and relaxivity techniques in pelvic tumorsKatharine J Lankester
Department of Medical Oncology, Mount Vernon Hospital, Northwood, Middlesex, UK
J Magn Reson Imaging 25:796-805. 2007.... - Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatmentNirupa Murugaesu
Department of Medical Oncology, Charing Cross Hospital, London, United Kingdom
J Clin Oncol 24:4862-6. 2006..This might help to select patients for risk-adapted treatment. There is need for improvement of therapeutic strategies after relapse... - Controversies in the management of germ cell tumours of the ovaryDaniel M Patterson
Mount Vernon Cancer Centre, Northwood, Middlesex, UK
Curr Opin Oncol 18:500-6. 2006....